Nilotinib 641571-10-0
We specialized in APIS/ Intermediates and Focus on Technical more than 10 years.we have a perfect research and development technology and manufacturing. We have more advantages of technical and price.
Nilotinib was approved as Tasigna in the USA and the EU for drug-resistant chronic myelogenous leukemia (CML).In June 2006, a Phase I clinical trial found nilotinib has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (trade name:Gleevec [USA]/ Glivec [Europe/Australia/Latin America]), another tyrosine kinase inhibitor currently used as a first-line treatment. In that study 92% of patients (already resistant or unresponsive to imatinib) achieved a normal white blood cell counts after five months of treatment. The drug carries a black box warning for possible heart complications.
CAS NO:162515-68-6
CAS NO:142569-70-8
CAS NO:113020-21-6
CAS NO:3697-66-3
CAS NO:1750-42-1
CAS NO:168960-19-8
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View